Literature DB >> 32909980

Cannabinoids for the Treatment of Opioid Use Disorder: Where is the Evidence?

Joji Suzuki1, Roger D Weiss.   

Abstract

With the growing public interest in the potential therapeutic benefits of cannabis and cannabinoids in the treatment of opioid use disorder (OUD), some states have now either added or proposed to add OUD as an indication for their state's medical marijuana program. However, these initiatives are based on weak evidence which at present do not support the listing of cannabis or cannabinoids as a treatment for OUD. Nevertheless, studying the potential therapeutic applications of carefully chosen components of cannabis or cannabinoids to treat specific aspects of OUD is not without scientific merit. Given the high rates of treatment discontinuation among those taking medications for OUD, interventions that further improve clinical outcomes are especially needed. The potential therapeutic applications of cannabis and cannabinoids in the treatment of OUD are worthy of further study, but it should be conducted with the same rigor that we expect of all pharmaceutical products. Until we have more research to show their efficacy, policy makers and clinicians should refrain from portraying cannabis and cannabinoids as evidence-based treatments for OUD.
Copyright © 2020 American Society of Addiction Medicine.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 32909980      PMCID: PMC7986228          DOI: 10.1097/ADM.0000000000000711

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   4.647


  14 in total

Review 1.  Cannabis: An Overview of its Adverse Acute and Chronic Effects and its Implications.

Authors:  Talitha C Ford; Amie C Hayley; Luke A Downey; Andrew C Parrott
Journal:  Curr Drug Abuse Rev       Date:  2017

2.  Should Physicians Recommend Replacing Opioids With Cannabis?

Authors:  Keith Humphreys; Richard Saitz
Journal:  JAMA       Date:  2019-02-19       Impact factor: 56.272

3.  Cannabis Use and Risk of Prescription Opioid Use Disorder in the United States.

Authors:  Mark Olfson; Melanie M Wall; Shang-Min Liu; Carlos Blanco
Journal:  Am J Psychiatry       Date:  2017-09-26       Impact factor: 18.112

4.  The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.

Authors:  Adam Bisaga; Maria A Sullivan; Andrew Glass; Kaitlyn Mishlen; Martina Pavlicova; Margaret Haney; Wilfrid N Raby; Frances R Levin; Kenneth M Carpenter; John J Mariani; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2015-07-08       Impact factor: 4.492

5.  Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans.

Authors:  Michelle R Lofwall; Shanna Babalonis; Paul A Nuzzo; Samy Claude Elayi; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2016-05-10       Impact factor: 4.492

6.  Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: A case series.

Authors:  Sukhpreet Klaire; Rebecca Zivanovic; Skye Pamela Barbic; Raman Sandhu; Nickie Mathew; Pouya Azar
Journal:  Am J Addict       Date:  2019-03-22

7.  Cannabis use during methadone maintenance treatment for opioid use disorder: a systematic review and meta-analysis.

Authors:  Heather McBrien; Candice Luo; Nitika Sanger; Laura Zielinski; Meha Bhatt; Xi Ming Zhu; David C Marsh; Lehana Thabane; Zainab Samaan
Journal:  CMAJ Open       Date:  2019-11-19

Review 8.  Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage.

Authors:  Yasmin L Hurd; Michelle Yoon; Alex F Manini; Stephanie Hernandez; Ruben Olmedo; Maria Ostman; Didier Jutras-Aswad
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

9.  Association of Medical and Adult-Use Marijuana Laws With Opioid Prescribing for Medicaid Enrollees.

Authors:  Hefei Wen; Jason M Hockenberry
Journal:  JAMA Intern Med       Date:  2018-05-01       Impact factor: 21.873

10.  Association between medical cannabis laws and opioid overdose mortality has reversed over time.

Authors:  Chelsea L Shover; Corey S Davis; Sanford C Gordon; Keith Humphreys
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-10       Impact factor: 11.205

View more
  2 in total

1.  The prevalence and pattern of cannabis use among patients attending a methadone treatment clinic in Nairobi, Kenya.

Authors:  Elizabeth Wambui Ngarachu; Sarah Kanana Kiburi; Frederick R Owiti; Rachel Kangethe
Journal:  Subst Abuse Treat Prev Policy       Date:  2022-02-15

2.  Cannabidiol Effect on Cue-Induced Craving for Individuals with Opioid Use Disorder Treated with Buprenorphine: A Small Proof-of-Concept Open-Label Study.

Authors:  Joji Suzuki; Bianca Martin; Sara Prostko; Peter R Chai; Roger D Weiss
Journal:  Integr Med Rep       Date:  2022-08-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.